Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy
Metrics: PDF 1347 views | HTML 2228 views | ?
Hongyu Liu1,*, Ling Chen1,*, Yaojun Peng2, Songyan Yu3, Jialin Liu1, Liangliang Wu2, Lijun Zhang2, Qiyan Wu2, Xin Chang4, Xinguang Yu1 and Tianyi Liu2
1Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China
2Key Laboratory of Cancer Center, Chinese PLA General Hospital, Beijing 100853, China
3Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China
4Department of Clinical Laboratory, Weihai Municipal Hospital, Weihai 264200, Shandong, China
Tianyi Liu, email: email@example.com
Xinguang Yu, email: firstname.lastname@example.org
Keywords: tumor derived exosomes, dendritic cells, immunotherapy
Received: October 21, 2016 Accepted: April 29, 2017 Published: September 11, 2017
Exosomes are vesicles that can be secreted by many types of cell and released into the extracellular space. Studies have found that tumor derived exosomes (TEXs) can promote tumor growth and metastasis, as well as inhibit immune response through transferring their genetic information to the recipient cells. Given their functions in tumor progression, TEXs are considered as promising biomarkers for early detection of human malignancy. Dendritic cells (DCs), a type of antigen presenting cells, can induce tumor-specific T cell immune responses in carcinogenesis. Growing evidences have demonstrated that the matured DCs induced by TEXs exhibit enhanced anti-tumor effects that may be applied for cancer immunotherapy. Thus in this review, according to the previous studies, we summarized the effects of DCs loaded with TEXs in cancer immunotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.